Mereo Biopharma Group Plc
MREO at a Glance
- Market cap
- $41.5M
- Revenue (TTM)
- $800,000
- EPS (TTM)
- $-0.15
- 52-week range
- $0 – $2
- Street target
- $1.94
Headquartered in One Cavendish Place, London Fiscal year ends December NASDAQ: MREO mereobiopharma.com
About Mereo BioPharma
Mereo BioPharma Group plc (NASDAQ: MREO) is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases. Its model pairs partnerships that provide validation and non-dilutive capital for late-stage development with retained commercial rights in key territories, particularly Europe.
Its pipeline has three rare disease product candidates:
- **Setrusumab (UX143)** for osteogenesis imperfecta. Partner Ultragenyx funds and leads global development, while Mereo retains EU and UK commercial rights. Two Phase 3 studies (Orbit and Cosmic) reported top-line results in December 2025, and the partners are now working with regulators on whether a path forward exists in pediatric patients.
- **Alvelestat (MPH-966)** for alpha-1 antitrypsin deficiency-associated lung disease. It is subject to an option and license agreement with Sentynl Therapeutics, a Zydus Lifesciences subsidiary, covering U.S. commercial and global manufacturing rights. Mereo retains rest-of-world rights and leads global development, with a Phase 3 study targeted for early 2027.
- **Vantictumab** for autosomal dominant osteopetrosis type 2. It is partnered with āshibio, which funds and leads development; Mereo retains EU and UK commercial rights.
Mereo has also out-licensed two other assets globally: leflutrozole for male infertility to ReproNovo, and navicixizumab for late-stage ovarian cancer to Feng Biosciences. The company's ADSs each represent five ordinary shares. Updated
Frequently Asked Questions
What does Mereo BioPharma do?
Mereo BioPharma Group plc (NASDAQ: MREO) is a clinical-stage biopharmaceutical company developing therapeutics for rare diseases. Its model pairs partnerships that provide validation and non-dilutive capital for late-stage development with retained commercial rights in key territories, particularly Europe.
What is the MREO stock price target?
The Wall Street consensus 12-month price target for MREO is $1.94.